Statins Get Quit. Wegovy Gets Endured. — What this summer's weight-loss boom reveals isn't the drug, but the weight of a disease

Wegovy makes four in five users sick; people wait for the next dose. Statins are nearly harmless; people quietly stop. What separates them was never the drug.

The same phrase — "side effect" — moves people in opposite directions. Handed a statin to lower cholesterol, many quietly stop: "my muscles ache." Handed Wegovy to lose weight, others endure days of nausea and vomiting, then wait for the next injection. Both are drugs with side effects. One gets abandoned; one gets tolerated. What separates them?

First, the statin — a "safe" drug

The statin is widely blamed for muscle pain. The British SAMSON trial complicated that story. Patients took the real drug, a placebo, and no pill at all, in rotating months. Their reported muscle-symptom scores came out essentially identical on the drug (16.3) and the placebo (15.4) — no statistical difference.

90%

Share of statin "muscle symptoms" traced to the nocebo effect — the act of taking a pill, not the drug itself (SAMSON trial).

In randomized trials, statins cause side effects only 1–5 percentage points more than placebo; in everyday practice, reports run as high as 30%. That gap is expectation. More striking still, half of the patients once labeled "statin-intolerant" were back on the drug six months later. On the numbers, the statin is nearly harmless. People quit it anyway.

Now, Wegovy — a "hard" drug

Wegovy is the opposite. Its side effects are real and common. Over two years in the STEP 5 trial, 82.2% of people on semaglutide had gastrointestinal trouble — nausea, diarrhea, vomiting, constipation — against 53.9% on placebo, a 28-point excess. Four in five felt sick. The U.S. FDA label spells out risks of pancreatitis, gallbladder disease, and kidney injury.

82.2%

Semaglutide users in the STEP 5 trial who had gastrointestinal side effects, versus 53.9% on placebo (Nature Medicine).

And yet people stay. Across the STEP trials, 95.5% of those who felt sick finished the course anyway, and only 4.3% quit for good because of side effects. In South Korea, where obesity treatment isn't covered by national health insurance — a four-week pen runs ₩200,000–400,000 (roughly $135–270), about ₩1.75 million (~$1,200) over six months — clinics that open only on weekends to dispense the drugs have sprouted, and worldwide the supply runs chronically short.

Clinicians say the same. Lee Seung-hoon, a physician at Seoul National University Hospital, told a Korean talk show that Wegovy's side effects dwarf a statin's — he himself vomits hard after a single dose — yet many patients who react that way are, in his words, "ready to endure it." Not everyone does: some feel nothing, some lose no weight, some binge their way back after stopping. But the trend is unmistakable — most are willing to pay the price knowingly.

What tipped the scale wasn't the drug

So what separates the two isn't safety. The nearly harmless statin gets dropped; the far harsher Wegovy gets endured. The difference lies not in the drug but in how much the disease hurts, day to day.

High cholesterol doesn't hurt. You can't see it in the mirror, and no stranger's glance lands on it. So one twinge of muscle pain is enough: "this drug isn't for me." Obesity is different. It is felt every day — in the mirror, in clothes, in other people's eyes. A few days of nausea is a price worth paying against that weight.

And here the real assumption flips. For decades, obesity was treated as a failure of will: eat less, move more, and if you can't, you're lazy. The Wegovy boom shows the reverse. That people absorb the side effects and the steep cost to stay on the drug is itself evidence that obesity is not a habit willpower can suppress, but a disease that needs treatment. As an obesity physician told the Harvard Gazette, no one tells a cancer patient — or anyone with a chronic illness — to drop their medicine and tough it out on willpower; yet that is precisely the standard reserved for obesity.

And the "medicine for a disease" is outgrowing its label. Wegovy has been shown to cut cardiovascular events, not just weight (the SELECT trial), and some argue it is retracing the path of the statin — a cholesterol drug that turned out to do far more.

That question now sits at a policy crossroads. Recently, France became the first European Union country to put Wegovy and Mounjaro (tirzepatide, a rival drug) on public insurance for severely obese patients, covering 65% of the cost; Japan, after a surge in Mounjaro sales, will cut its price by 25% across all doses from August. Both moves treat the drugs as chronic-disease therapy, not cosmetics. South Korea, by contrast, still leaves them entirely out of pocket, while its Ministry of Food and Drug Safety moves to classify the GLP-1 class as "drugs at risk of misuse." To some it is a slimming fad; to others, lifelong medicine for a disease. Over the same syringe, society hasn't decided which.

Note: GLP-1 drugs like Wegovy are prescription medicines that require medical supervision. Their benefits and risks vary from person to person, and weight often returns once treatment stops. A conversation with a clinician should come before any cosmetic self-prescribing.

The Takeaway

Do side effects make people avoid a drug? People endure Wegovy, whose side effects are far more common, and quit statins, which have almost none. What tipped the scale wasn't the drug's safety — it was how much the disease is felt, every single day.

Sources

이 블로그 검색

Daily Woody